Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype-Reference-Cited by-同舟云学术

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

Published:2011-04-14 Issue:22 Volume:117 Page:5058-5066
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hernandez-Ilizaliturri Francisco J.,Deeb George,Zinzani Pier L.,Pileri Stefano A.,Malik Farhana,Macon William R.,Goy Andre,Witzig Thomas E.,Czuczman Myron S.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.26135/fullpdf

Reference33 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin.,2010

2. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature.,2000

3. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma;Rosenwald;N Engl J Med.,2002

4. Gene expression profiling of lymphoid malignancies;Staudt;Annu Rev Med.,2002

5. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray;Hans;Blood.,2004

Cited by 274 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-07-03

2. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma;New England Journal of Medicine;2024-06-20

3. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP;Blood Advances;2024-04-28

4. New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?;Journal of Clinical Medicine;2024-03-27

5. Therapeutic options for rituximab-resistant patients;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024